Hormone Receptor (HR)- positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer

1
(No Transcript)
2
HR-positive/HER2-negative Breast Cancer
If cancerous cells get signals from the hormone
progesterone that could promote growth, then
known as progesterone receptor-positive
(PR) breast cancer. Breast cancer that is
ER-positive or PR-positive falls under the
category of hormone receptor- positive (HR)
breast cancer.
HR-positive cancer is usually treated with
hormone therapies or a combination of hormone
therapy with targeted therapy to help stop tumor
growth first. There are more number of cases for
breast cancer in women observed in comparison to
the men.

• DelveInsight 2019 All rights reserved

3
HR-positive/ HER2-negative Breast Cancer
Epidemiology
Among the various subtypes of the disease,
HR/HER2- occupies the maximum patient pool,
followed by the number of those with Triple
negative and HR-positive/HER2 negative.  
The United States show higher Breast Cancer
incidence with 266,120 cases in 2017 and Japan
accounts for the second highest breast cancer
incident cases with 89,100.
The total incident population Breast Cancer in
the 7MM is expected to grow at CAGR of 0.83
during study period 20172028.
Among the EU-5 countries, Germany ranked first
with 71,585 cases whereas Spain has the least
number of breast cancer incident cases.

• DelveInsight 2019 All rights reserved

4
HR-positive/ HER2-negative Breast Cancer Market
Among the EU-5 countries, Germany had the highest
HR-positive/HER2-negative breast cancer market
size in 2017 that accounts for 25.51 of the
total market.
The United States had the HR-positive/HER2-negativ
e breast cancer highest market size in 2017 that
accounts for 83.96 of the total market.
HR-positive/ HER2-negative Breast market size in
the 7MM countries was observed to be USD 5,237.2
million in 2017.
HR-positive/HER2-negative breast cancer market
size was found to be USD 4216.4 million in 2017.

• DelveInsight 2019 All rights reserved

7MM includes - USA, EU-5 (Germany, Spain,
Italy, France and UK), Japan
5
HR-positive/ HER2-negative Breast Cancer Market
Outllook
HR-positive/ HER2-negative Breast Cancer
Emerging Drugs and Companies
02
01
03
04
Company- Jiangsu HengRui Medicine Drug- SHR6390
Company- Immunomedics Drug- IMMU-132
Company- Odonate Therapeutics Drug- TESETAXEL
Company- Roche Group Drug- RG7440

• DelveInsight 2019 All rights reserved

6
Complete Information
For complete information on Hormone Receptor
(HR)-positive/ Human Epidermal Receptor 2
(HER2)-negative Breast Cancer Market Insights,
Epidemiology and Market Forecast2028 please
click the link below
CLICK HERE
OR
Write Us At 
info_at_delveinsight.com

• DelveInsight 2019 All rights reserved

7
About DelveInsight
MISSION
ABOUT
VISION
DelveInsight is a premier Business Consulting and
Market Research firm focused exclusively on the
life science segment. With a wide array of smart
end-to-end solutions, the firm helps the global
Pharmaceutical and Bio-Tech companies formulate
prudent business decisions for improving their
performances to stay ahead of the competitors.
To be the most trusted market research business
consulting firm in the world and to continue
enable the Pharma Bio-Tech companies to achieve
their goals with the best strategic insight and
competitive solution. The vision also is
inclusive of becoming a one-stop solution
provider for the entire gamut of drug development
process.
To provide insights across the value chain and
helping the organization to take a prudent
business decision through the use and analysis of
actionable market intelligence. The mission also
is to provide the most effective result and
efficient service with utmost client care for
maintaining a long-term relationship with them.

• DelveInsight 2019 All rights reserved

8
Service Offerings By Delveinsight
OPPORTUNITY ASSESSMENT
FORECASTING
PIPELINE
REPORT STORE
COMPETITIVE ANALYSIS
CONSULTING
MARKET INTELLIGENCE
PHARMDELVE

• DelveInsight 2019 All rights reserved

9
Contact Us
blog/delveInsight/
info_at_delveinsight.com
91-11-4568 9769
twitter/delveInsight
LinkedIn/delveInsight
www.delveinsight.com

• DelveInsight 2019 All rights reserved

10
THANK YOU